These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 33963476)

  • 1. A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
    El-Khouly FE; Veldhuijzen van Zanten SEM; Jansen MHA; Bakker DP; Sanchez Aliaga E; Hendrikse NH; Vandertop WP; van Vuurden DG; Kaspers GJL
    J Neurooncol; 2021 Jun; 153(2):263-271. PubMed ID: 33963476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
    Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
    J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
    Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
    McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
    J Neurosurg Pediatr; 2021 Oct; 28(4):371-379. PubMed ID: 34359048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
    Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
    J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma.
    Veldhuijzen van Zanten SEM; El-Khouly FE; Jansen MHA; Bakker DP; Sanchez Aliaga E; Haasbeek CJA; Wolf NI; Zwaan CM; Vandertop WP; van Vuurden DG; Kaspers GJL
    J Neurooncol; 2017 Nov; 135(2):307-315. PubMed ID: 28748343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma.
    Özkan A; Yağcı Küpeli B; Küpeli S; Sezgin G; Bayram İ
    Childs Nerv Syst; 2024 Jun; 40(6):1671-1680. PubMed ID: 38478066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
    J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
    Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
    Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma.
    Mueller S; Kline C; Stoller S; Lundy S; Christopher L; Reddy AT; Banerjee A; Cooney TM; Raber S; Hoffman C; Luks T; Wembacher-Schroeder E; Lummel N; Zhang Y; Bonner ER; Nazarian J; Molinaro AM; Prados M; Villanueva-Meyer JE; Gupta N
    Neuro Oncol; 2023 Nov; 25(11):2074-2086. PubMed ID: 37318058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
    Macy ME; Kieran MW; Chi SN; Cohen KJ; MacDonald TJ; Smith AA; Etzl MM; Kuei MC; Donson AM; Gore L; DiRenzo J; Trippett TM; Ostrovnaya I; Narendran A; Foreman NK; Dunkel IJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
    Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
    Torcuator R; Zuniga R; Loutfi R; Mikkelsen T
    J Neurooncol; 2009 Jul; 93(3):409-12. PubMed ID: 19139822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.
    Fried I; Lossos A; Ben Ami T; Dvir R; Toledano H; Ben Arush MW; Postovski S; Abu Kuidar A; Yalon M; Weintraub M; Benifla M
    J Neurooncol; 2018 Jan; 136(1):189-195. PubMed ID: 29143272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
    Janssens GO; Gandola L; Bolle S; Mandeville H; Ramos-Albiac M; van Beek K; Benghiat H; Hoeben B; Morales La Madrid A; Kortmann RD; Hargrave D; Menten J; Pecori E; Biassoni V; von Bueren AO; van Vuurden DG; Massimino M; Sturm D; Peters M; Kramm CM
    Eur J Cancer; 2017 Mar; 73():38-47. PubMed ID: 28161497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
    Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
    Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
    Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
    Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.